Background: Secondary hyperparathyroidism (SHPT) in chronic kidney disease is associ-
Introduction
Secondary hyperparathyroidism (SHPT) begins early in the course of chronic kidney disease (CKD) and is characterised by progressive parathyroid gland hyperplasia, excessive parathyroid hormone (PTH) secretion and abnormalities in calcium and phosphate metabolism. As renal function declines SHPT becomes almost ubiquitous and results in bone and endocrine abnormalities, together with extra-osseous calcification. SHPT has been associated with left ventricular dysfunction, 1 myocardial fibrosis, 2 dyslipidaemia, 3 peripheral neuropathy 4 and anaemia as a result of reduced red blood cell survival and bone marrow fibrosis. 5 SHPT is a significant component of the well-recognised broader clinical syndrome encompassing mineral, bone and cardiovascular abnormalities that develop as a complication of CKD -CKDmineral and bone disorder (CKD-MBD).
Traditional management of SHPT is aimed at controlling phosphate by means of restricting intake, optimising dialysis and administering phosphate binders, as well as modulating calcium balance and suppressing PTH release with activated vitamin D. Despite traditional management, patients with severe and progressive disease may require surgical management with a parathyroidectomy. Although parathyroidectomies improve biochemical parameters and clinical symptoms related to severe SHPT, they are associated with an increased 30-day mortality and risk of re-hospitalisation with hypocalcaemia. 6 Surgical management also may not be suitable for older patients with complex comorbidities, which encompasses a large proportion of dialysis patients in the Western world. In some cases, the effect of parathyroidectomy is also transient, with recurrence in up to 14%. 7 The only oral calcimimetic available to date is cinacalcet, which provides a medical alternative to parathyroidectomy and acts as a positive allosteric modulator of the calcium-sensing receptor reducing PTH secretion. Cinacalcet reduces PTH [8] [9] [10] [11] and, in patients on dialysis, cinacalcet plus low doses of activated vitamin D reduces progression of coronary artery calcification score volume when compared to higher activated vitamin D therapy. 12 In Australia, government reimbursement for cinacalcet was introduced in 2009, but was contingent on proof of efficacy and cost-effectiveness from the pivotal Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis (EVOLVE) trial. 13 Following publication of EVOLVE, which showed no change in the unadjusted composite primary end-point of cardiovascular mortality and morbidity in patients on cinacalcet, government reimbursement for cinacalcet in Australia was withdrawn in August 2015 due to the lack of evidence of cost-effectiveness. Secondary analyses of the study did report benefits, including reduced cardiovascular mortality in patients over 65 years of age, 14 a reduction in the risk of calciphylaxis 15 and possibly fracture risk. 16 Globally, predictive Markov models were able to demonstrate cost-effectiveness in Italy 17 and Japan, 18 especially for patients unsuitable for parathyroidectomy. Economic analysis in Australia showed benefit in reducing parathyroidectomy rates, as well as clinical benefits in those over 65 years; however, given financial feasibility was not met, funding of this medication was not continued. The hypothesis of our present study was that withdrawal of cinacalcet in dialysis patients with SHPT in Australia may be associated with changes to biochemical and clinical outcomes, including parathyroidectomy rates and prescribing practices.
Methods

Study design
We performed a retrospective observational study involving maintenance dialysis patients who had ceased cinacalcet therapy after August 2015. The aim was to assess the impact on clinical outcomes and biochemical parameters of mineral metabolism after withdrawal from cinacalcet in patients on dialysis. The study protocol was approved by the local ethics committee at Melbourne Health (The Royal Melbourne Hospital). Reciprocal ethics and governance approval was arranged at each site involved in the study. 
Study population
Study end-points
The primary end-point was change in biochemical outcome measures over a 12-month period. Patients were excluded from final analysis if they underwent a renal
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Biomarker assessment
Biochemical data were obtained from each nephrology unit. All hospitals measure intact PTH, although a variety of testing platforms for PTH are currently used by pathology departments. All patients had measurements over the course of 12-month study period performed at the same centre and on the same platform, which reduced intra-sample variability. There remains some variability between different intact PTH platforms currently available 19 ; however, variability between different platforms used across units in different states was unavoidable.
Statistical analysis
All data are summarised and results reported as mean (AEstandard deviation (SD)) or median (interquartile range (IQR)) for continuous data and number (%) for categorical variables. Paired t-test and Wilcoxon-signed rank test were used for between-group comparisons. Categorical variables were analysed with Chi-squared test. Continuous variables were compared with one-way repeated measure analysis of variance if normally distributed or with Freidman test if the distribution was skewed. Twotailed P values <0.05 were considered statistically significant. All statistical analyses were performed using SPSS version 21.0 for Macintosh (SPSS, Chicago, IL, USA).
Results
Demographics and clinical characteristics
The study included 228 patients in whom cinacalcet had been ceased between August and December 2015. This represents 17.7% of dialysis patients across the 11 units. Baseline characteristics are shown in Table 1 . The mean age and median time on dialysis were 63 AE 15 years and 5.7 (IQR 3-8) years respectively. Thirty-seven percent of patients had diabetes, 74% had a history of hypertension and 38% had a history of ischaemic heart disease.
Clinical outcomes
Over a 2-year period, 26 patients underwent parathyroidectomies, 19 of which occurred within the first 12-month period. There were three episodes of calciphylaxis, eight non-vertebral fractures and 50 deaths (26 in the first 12 months and 24 in the subsequent 12 months), with an annual overall mortality rate of 11.0%. Deceased patients were older, with a mean age of 69 AE 11 years (P = 0.005); however, the median time on dialysis (6 (IQR 3-7) years, P = 0.9) and associated comorbidities including hypertension (P = 0.70), diabetes (P = 0.14) and ischaemic heart disease (P = 0.14) were similar in both cohorts.
Biochemical outcomes
Thirty-five patients were excluded from 12-month analysis of biochemical changes and prescribing practices. Demographics and clinical features of this cohort are described in Table 2 . Nineteen underwent parathyroidectomies, eight recommenced cinacalcet therapy, with access to medication through an industry-sponsored special access scheme, and eight received a kidney transplant.
There was an increase in PTH from 54 pmol/L (27-90 pmol/L) to 85 pmol/L (41-139 pmol/L) at 12 months (P < 0.001), with the greatest change occurring by 6 months (P < 0.001) (Fig. 1) . Correspondingly, serum calcium increased from 2.30 AE 0.2 mmol/L to 2.50 AE 0.1 mmol/L (P < 0.001), and phosphate remained unchanged over the observation period (P = 0.84). There were 54 episodes of hypercalcaemia (serum corrected calcium >2.6 mmol/L) at 6 months, with 31 episodes occurring at 12 months; this was significantly increased from 19 episodes of hypercalcaemia identified at baseline (P = 0.002). There was an increase in alkaline phosphatase (ALP) from 123 IU/L (92-176 IU/L) to 143 IU/L (102-197 IU/L) at 12 months (P < 0.001). Inflammatory markers, including C-reactive protein and ferritin remained stable over 12 months, and there was a fall in serum albumin from 35.5 AE 4.6 g/L to 34.5 AE 4.5 g/L, P = 0.01. Table 3 summarises baseline, 6-month and 12-month values for biochemical outcomes in the study cohort.
Changes in prescribing practices
The median daily dose of cinacalcet prior to medication cessation was 30 mg (30-60 mg). At baseline, 38% of patients (n = 74) were on a calcium-based phosphate binder and 66% (n = 127) on a non-calcium-based phosphate binder; 26% (n = 56) were on two phosphate binders and 21% (n = 46) were not taking any phosphate binder. At baseline, active vitamin D use was high at 65% (n = 125) and 26% (n = 51) were on nutritional vitamin D. By 12 months following cinacalcet withdrawal, phosphate binder use was significantly reduced, with 29% (n = 52, P = 0.01) on a calcium-based binder and 50% (n = 97, P = 0.008) on a non-calcium-based binder. Active vitamin D use also reduced by 12 months to 48% (n = 93), P = 0.03. However, of the patients who remained on active vitamin D their dose was increased from 1.6 AE 0.8 μg/week to 2.2 AE 1.3 μg/week (P = 0.005). There was no change in cholecalciferol administration (P = 0.23). Table 4 describes prescribing 
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Discussion
Our study of 228 dialysis patients from 11 nephrology centres across Australia is the first to show clinical and biochemical outcomes of cinacalcet withdrawal in a large cohort. We report that cinacalcet cessation, when previously used for the management of SHPT, was not associated with increased clinical outcomes after 2 years from withdrawal when compared to reported outcomes in the Australian dialysis population, apart from the rate of parathyroidectomy. Associated biochemical changes, however, included a rise in PTH, calcium and ALP, no corresponding change in serum phosphate and a fall in serum albumin in the first 12 months after medication withdrawal.
Following cinacalcet withdrawal, there was a statistically significant increase in ALP, which may represent increased bone turnover. Recent publications suggest cinacalcet use may improve bone metabolism and is associated with reduced bone turnover markers including bone-specific ALP, osteocalcin and beta-crosslaps. 20 Cunningham et al. 21 reported reduced parathyroidectomy, fracture and cardiovascular hospitalisation rates with cinacalcet use in a combined analysis of four clinical trials, and secondary analysis of the EVOLVE trial identified a trend towards reduced rates of fractures with cinacalcet use, particularly in older patients. 16 The fracture rate in our cohort was relatively small with only eight clinically evident fractures during the study period, although the incidence of fracture may have been under-reported by units. Fractures seen in primary care settings and asymptomatic vertebral fractures may have potentially not been included.
With regards to clinical outcomes, 11% of patients underwent a parathyroidectomy within 2 years of medication cessation, equating to an 86/1000 persons-year parathyroidectomy rate. There was no observed increase in calciphylaxis, with three episodes identified in the cohort over the 24-month study period. The mortality rate of the cohort was 11% per year, which is comparable to current published Australian dialysis mortality data for patients in a similar age group. 22 As vascular calcification and associated cardiovascular mortality and morbidity related to SHPT may take many years to develop, this cohort requires further follow up to identify if there are potentially longer-term associations with cinacalcet withdrawal.
Parathyroidectomy rates are not currently recorded in the Australian and New Zealand Dialysis and Transplant registry (ANZDATA), unlike other parameters including cardiovascular disease and cancer. Therefore, this study is limited in being able to identify increased rates of parathyroidectomy since reimbursement of cinacalcet ceased. Certainly, within one centre at The Royal Melbourne Hospital, we have seen a 69% increase in the rate of parathyroidectomies since 2015. Data from Canada following the public formulary listing of cinacalcet showed 23 Multiple studies have highlighted the short-term risks associated with parathyroidectomies in patients on dialysis. 6, 24 A review of clinical outcomes following parathyroidectomy using US Renal Data System (USRDS) data, demonstrated a 2% 30-day mortality and 23.8% re-hospitalisation rate following surgery, together with a 39% increase in hospitalisation rate in the year following parathyroidectomy. 24 Long-term mortality in younger dialysis patients may be better with parathyroidectomy compared with medical management 25 ; however, it is difficult to generalise this potential benefit to our study cohort, given the average age in our study cohort was 63 years, with a higher percentage of comorbidities including diabetes and ischaemic heart disease.
Patient preference in regards to treatment of SHPT with cinacalcet versus parathyroidectomy has not been assessed to our knowledge. The impact on quality of life with parathyroidectomy versus cinacalcet has recently been examined in a systematic review of eight studies. 26 Although a direct comparison between the two interventions could not be made, parathyroidectomy was associated with improvement in short-and long-term quality of life, including improvement in itch, joint pain and muscle weakness, whereas no difference was seen in quality of life with the use of cinacalcet. It is possible that reduction in PTH with surgery compared to medical suppression is more beneficial; however, it is unlikely that a head-to-head comparison will ever be undertaken.
Reduced use of activated vitamin D from 65% to 48% was not unexpected, because the use of cinacalcet allows clinicians to target lower PTH values by enabling increased dosing with activated vitamin D with a reduced risk of hypercalcaemia. Nevertheless, there was no associated increase in serum phosphate over a 12-month period after cinacalcet withdrawal, suggesting that cinacalcet alone was insufficient to overcome the biochemical effects of hyperphosphataemia resulting from increased calcitriol use. In fact, one consideration is whether cinacalcet availability emphasises the potential to achieve lower PTH values, leading to higher calcitriol and phosphate binder requirements. As oversuppression of PTH and higher phosphate binder use may have adverse consequences, particularly when calcium-based binders are used, the question arises as to longer-term patient-level benefits of more complex combined therapies that include cinacalcet.
Limitations of our study include its retrospective observational nature and therefore we do not have a control group to compare identified clinical and biochemical changes. Comparing mortality and morbidity data in our cohort to published data in the general Australian dialysis population involves selection bias as we have studied a cohort of individuals previously prescribed cinacalcet based on clinical indication as determined by their treating clinicians. Also, not all units across Australia were involved in data collection and there was a short duration of follow up. Furthermore, we were unable to collect comprehensively all morbidity outcomes, including fracture rates and types of cardiovascular events, as well as changes in dosing of phosphate binders in all study participants, given the study's retrospective nature. Another limitation is that given the variability between different PTH analysis platforms, it is possible we have over-or underestimated the change in PTH over the study period. Strengths of our study include a large data set across 11 Australian centres with varying geographical locations, which provides a unique insight into the effects of cinacalcet withdrawal, perhaps not possible in many another countries. We have also collected comprehensive national biochemical parameters and parathyroidectomy rates in Australia in the era following withdrawal of cinacalcet reimbursement.
Conclusion
For patients in the Australian dialysis population who withdrew from cinacalcet therapy, median values of PTH exceeded the Kidney Disease Improving Global Outcomes (KDIGO) CKD-mineral and bone disorder guidelines-suggested upper target range of 9 times the upper range of the PTH assay, calcium and ALP values rose and there was no change in serum phosphate. The parathyroidectomy rate was 86/1000 patient-years over the first 24 months from withdrawal. Longer-term follow up will allow greater insight into associated future cardiovascular morbidity, mortality and fracture rates.
